Protalix BioTherapeuticsNYSE American: PLX

PHILADELPHIA, PA / ACCESSWIRE / June 11, 2024 / Kaskela Law LLC announces that it is investigating Protalix BioTherapeutics, Inc. (NYSE:PLX) ("Protalix") on behalf of the company's shareholders. Since May 2023, shares of Protalix common stock have declined in value from a trading price of approximately $3.25 per share to a current trading price of below $1.25 per share, a decline of over 61% in value.

Protalix BioTherapeutics, Inc. (PLX) Q4 2023 Earnings Call Transcript

Corporate presentation scheduled for Monday, February 26, 2024 at 1:00 PM ET CARMIEL, Israel , Feb. 23, 2024 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell based protein expression system, today announced that it will attend and present at the 2024 BIO CEO & Investor Conference taking place February 26-27, 2024 at the New York Marriott Marquis in New York City. Management is scheduled to give a corporate overview at the BIO CEO & Investor Conference on Monday, February 26, 2024 at 1:00 PM ET at the Plymouth Room and will be available to participate in one-on-one partnering meetings with registered investors and other conference attendees.

Company to host conference call and webcast at 8:30 a.m. EDT CARMIEL, Israel , July 31, 2023 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell–based protein expression system, today announced that it will release its financial results for the second quarter ended June 30, 2023 and provide a business update on Monday, August 7, 2023.